MediGene's validation play with Schering

MediGene AG was to announce today that it has formed a worldwide alliance to develop its Viral Vaccine with Schering AG for the treatment of precancerous cervica

MediGene (Munich, Germany) is using protein fusion technology to develop a chimeric viral-like particle (CVLP) capsid designed both to vaccinate against HPV infection and to treat HPV infected patients. The

Read the full 562 word article

How to gain access

Continue reading with a
two-week free trial.